This condition — the plain-language one-pager.

What is Pulmonary Fibrosis / ILD?Diagnosis

Interstitial Lung Disease (ILD) is a group of conditions where the tissue between the air sacs of the lungs becomes inflamed and scarred. Idiopathic Pulmonary Fibrosis (IPF) is the most common ILD with progressive scarring. Once scar tissue forms, it does not reverse — but antifibrotic medications can slow progression dramatically, and many ILDs (sarcoidosis, hypersensitivity pneumonitis, autoimmune-related) are partially reversible if caught early. Time is lung tissue.

• Classic symptoms — Slowly worsening shortness of breath (especially with exertion), dry cough, fatigue, clubbed fingers, weight loss. Often dismissed as "getting older" or "deconditioning" for years.
• Top types — Idiopathic Pulmonary Fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis (HP), connective-tissue-disease-related ILD (rheumatoid, scleroderma, polymyositis), drug-induced ILD (amiodarone, methotrexate, nitrofurantoin), occupational (asbestosis, silicosis).
• Workup — High-resolution CT (HRCT) is the diagnostic backbone, sometimes followed by bronchoscopy or surgical lung biopsy. Pulmonary function tests (PFTs) — particularly DLCO and FVC — track progression. 6-minute walk test grades exercise tolerance and oxygen needs.
• Modern treatment — Antifibrotics (pirfenidone, nintedanib) for IPF and progressive fibrotic ILDs slow FVC decline. Steroids + immunosuppressants for inflammatory ILDs (sarcoid, HP, CTD-ILD). Pulmonary rehab. Oxygen as needed. Lung transplant evaluation for advanced disease — the only therapy that prolongs life in end-stage IPF.

Pulmonary rehab + oxygen + antifibrotics — the modern triadKnow your plan

A diagnosis of ILD used to feel like nothing could be done. Modern care has changed that. Pulmonary rehab improves quality of life as much as a major medication; supplemental oxygen prevents pulmonary hypertension; antifibrotics slow the curve. Each layer matters.

• Pulmonary rehabilitation — supervised 8–12 weeks. Covered by Medicare and most insurers. Improves walking distance, mood, and survival.
• Antifibrotic therapy if IPF or progressive fibrosing ILD — pirfenidone or nintedanib. Slow the FVC decline. Side effects (GI, photosensitivity) are real but manageable.
• Oxygen when SpO₂ < 88% at rest, sleep, or with exertion. Prevents pulmonary hypertension and right-heart failure.
• Vaccines — flu, COVID, pneumococcal, RSV, herpes zoster. Respiratory infections accelerate ILD.
• Lung transplant evaluation — referral early at major centers. Even if not yet eligible, the conversation starts the timeline.

Your daily Force FieldLive It

• Take antifibrotic daily if prescribed — pirfenidone (with food, sun protection) or nintedanib (with food). Manage GI side effects with dose titration + anti-emetics.
• Pulmonary rehab — every session. The single most under-prescribed, highest-leverage intervention in ILD.
• Oximeter at home; check at rest + with exertion. Use oxygen as prescribed; titrate up with activity, sleep, altitude.
• Vaccines current — flu, COVID, pneumococcal, RSV, shingles. Avoid sick contacts.
• No tobacco, no vaping; avoid second-hand smoke and high-pollution exposure.
• Identify and remove triggers for hypersensitivity pneumonitis (mold, birds, hot tubs, occupational dusts).
• Manage GERD aggressively — silent reflux drives IPF progression; PPI + lifestyle.
• Track symptoms in your Health Passport — walking distance, oxygen needs, cough, weight. Bring to every visit.
• Lung transplant evaluation at first signs of progression (FVC dropping, exertional desat) — better to be evaluated early than too late.

Red flags — call nowAction

• Call your clinic the same day for: new chest discomfort with exertion that goes away with rest (stable shortness of breath worth evaluating); a missed dose of antiplatelet or pulmonary medication; medication side effects (muscle aches, bleeding, GI symptoms).
• Bring up at next visit: any change in exercise tolerance, lipid follow-up timing, BP log review, smoking-cessation support, depression screening, sleep concerns.